Paper Details

  1. Home
  2. Paper Details

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

Author: BergThomas, BergkAlexandra, BernsmeierChristine, HeintgesTobias, HerrmannEva, HinrichsenHolger, HuberMiriam, HäussingerDieter, RasenackJens, ZeuzemStefan, von WagnerMichael

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigates whether shorter treatment durations for hepatitis C are possible for patients infected with genotypes 2 or 3, without compromising treatment success (sustained virologic response). Currently, the standard treatment is a 24-week course of pegylated interferon-alpha and ribavirin. The study aims to determine if a shorter treatment duration could be as effective.
Paper Details　
Original Abstract of the Article :
Standard therapy of patients with chronic hepatitis C virus (HCV) infected with HCV genotype-2 or -3 is the combination of pegylated interferon-alpha and ribavirin for 24 weeks. Whether shorter treatment durations are possible for these patients without compromising sustained virologic response rate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.gastro.2005.05.008

データ提供：米国国立医学図書館（NLM）

Treating Hepatitis C Genotypes 2 and 3: Exploring Shorter Treatment Durations

Hepatitis C is a serious liver disease that can lead to long-term health problems. The development of effective treatments has been a major breakthrough in combating this disease. This study explores the possibility of shortening treatment durations for patients with genotypes 2 and 3 of chronic hepatitis C.

The authors investigated whether reducing the standard 24-week treatment duration of pegylated interferon-alpha and ribavirin could still achieve sustained virologic response rates. While the study didn't provide a definitive answer, it raised important questions about the optimal treatment duration for these specific genotypes. The authors highlight the need for further research to explore shorter treatment options that balance effectiveness and patient well-being.

Hepatitis C Treatment: A Journey of Discovery

This research serves as a reminder that the field of medicine is constantly evolving. Researchers are constantly striving to improve treatment options, minimize side effects, and shorten treatment durations. This study encourages us to remain optimistic about the future of hepatitis C treatment.

Living with Hepatitis C: Maintaining a Healthy Lifestyle

As a camel who has roamed through diverse landscapes, I understand the importance of taking care of oneself. The same principle applies to living with hepatitis C. Following your doctor's recommendations, maintaining a healthy lifestyle, and engaging in regular exercise can significantly improve your overall health and well-being.

Dr. Camel's Conclusion

This study explores the possibility of shorter treatment durations for hepatitis C, highlighting the ongoing quest for more efficient and patient-friendly treatment options. It’s a reminder that medical research is a continuous journey of discovery, constantly seeking ways to improve patient care and outcomes.

Date :
  1. Date Completed 2005-09-07
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

16083709

DOI: Digital Object Identifier

10.1016/j.gastro.2005.05.008

Related Literature

Article Analysis
・Effective treatment of hepatitis c
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.